Session 1 – When Overall Survival Cannot Be a Primary Endpoint

Complete Session 1

Reflection on the challenge – Axel Glasmacher (CDDF, DE)

Pathway towards solutions – Chitkala Kalidas (Bayer, USA)

Pathway towards solutions – Elmar Schmitt (Merck Healthcare KGaA, DE)

Pathway towards solutions – Filip Josephson (EMA, SWE)

Session 2 – Endpoints in Expedited Approval Pathways

Complete Session 2, including the Panel Discussion

Patient Perspective – Hans Scheurer (MPE, NL)

Regulatory Perspective – Vishal Bhatnagar (FDA, USA)

HTA Perspective – Carole Longson (NICE, UK)

Session 3 – PRO Endpoints – Review of Strategies

Complete Session 3, including Panel Discussion

Patient Perspective – Jayne Galinsky (MPE, UK)

Regulatory Perspective – Vishal Bhatnagar (FDA, USA)

Industry Perspective – Paul Kamudoni (Merck Healthcare KGaA, UK)

HTA Perspective – Leeza Osipenko (London School of Economics, UK)

Academic Perspective – Corneel Coens (EORTC, BE)